Precision diagnosis and treatment of metastatic castration-resistant prostate cancer, 2024 ASCO-GU
10.3760/cma.j.cn112330-20240422-00193
- VernacularTitle:2024 ASCO-GU转移性去势抵抗性前列腺癌精准诊治进展
- Author:
Baijun DONG
1
;
Pengfei SHEN
;
Hao ZENG
;
Wei XUE
Author Information
1. 上海交通大学医学院附属仁济医院泌尿外科，上海 200127
- Keywords:
TKI-IO combination;
Tumor microenvironment;
Fusion partner
- From:
Chinese Journal of Urology
2024;45(4):261-264
- CountryChina
- Language:Chinese
-
Abstract:
The 2024 ASCO-GU Annual Meeting focused on precision diagnosis and treatment of metastatic castration-resistant prostate cancer (mCRPC). Studies showed that treatment strategies guided by molecular subtyping significantly prolonged patient survival. Meanwhile, China is actively exploring personalized treatment plans based on genetic testing. In the future, precision treatment based on genetic testing will be a crucial direction in mCRPC therapy.
